Role of inflammation in the development of atrial fibrillation
- 作者: Kryukov E.1, Cherkashin D.1, Kruzhalin E.1, Kutelev G.1, Alanicev A.1
-
隶属关系:
- Kirov Military Medical Academy
- 期: 卷 25, 编号 1 (2023)
- 页面: 107-120
- 栏目: Review
- URL: https://journals.rcsi.science/1682-7392/article/view/134092
- DOI: https://doi.org/10.17816/brmma112458
- ID: 134092
如何引用文章
详细
This study analyzed and demonstrated the role of inflammatory mechanisms and inflammation markers in the development of atrial fibrillation, their significance in the structural and electrical remodeling of the atria, and pharmacological agents that can be effective in reducing inflammation. Data were obtained from the analysis of retrospective and prospective studies and systematic reviews. The available domestic and foreign scientific studies indexed in PubMed, Google Scholar, and eLibrary.ru were analyzed. Atrial fibrillation is one of the most common arrhythmias in adults and is associated with many complications and mortality. The pathophysiological mechanisms of this arrhythmia remain completely unclear, and their search continues at the molecular level. Atrial fibrillation causes electrical and structural changes in the myocardium, which lead to further pathological transformations of the heart, and some of them are associated with inflammation, which has been demonstrated in studies on an experimental model and heart tissues of patients with this rhythm disorder. Whether inflammation is the cause of the development of this arrhythmia or its consequence is not clearly understood. Statins, corticosteroids, colchicine, genetically engineered biological drugs, which have a specific application point in the inflammatory cascade, and some other drugs, such as anticoagulants, polyunsaturated fatty acids, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and mineralocorticoid receptor antagonists, also take place in the treatment of atrial fibrillation. However, their applications are not clearly specified. Currently, research continuously aims at finding effective ways to prevent and treat this nosology. Thus, promising ways to reduce the role of inflammation in the occurrence, recurrence, diagnosis, and treatment of atrial fibrillation are relevant in the development of precision medicine.
作者简介
Evgeniy Kryukov
Kirov Military Medical Academy
Email: gogil01@mail.ru
ORCID iD: 0000-0002-8396-1936
SPIN 代码: 3900-3441
Scopus 作者 ID: 57208311867
MD, Dr. Sci. (Med.), professor
俄罗斯联邦, Saint PetersburgDmitriy Cherkashin
Kirov Military Medical Academy
Email: gogil01@mail.ru
ORCID iD: 0000-0003-1363-6860
SPIN 代码: 2781-9507
MD, Dr. Sci. (Med.), professor
俄罗斯联邦, Saint PetersburgEgor Kruzhalin
Kirov Military Medical Academy
编辑信件的主要联系方式.
Email: gogil01@mail.ru
ORCID iD: 0000-0002-8693-1281
SPIN 代码: 5994-9914
resident
俄罗斯联邦, Saint PetersburgGennady Kutelev
Kirov Military Medical Academy
Email: gogil01@mail.ru
ORCID iD: 0000-0002-6489-9938
SPIN 代码: 5139-8511
MD, Cand. Sci. (Med.)
俄罗斯联邦, Saint PetersburgAndrey Alanicev
Kirov Military Medical Academy
Email: gogil01@mail.ru
ORCID iD: 0000-0002-4135-5815
SPIN 代码: 6223-7758
MD, Cand. Sci. (Med.)
俄罗斯联邦, Saint Petersburg参考
- Chugh S, Havmoeller R, Narayanan K, et al. Worldwide Epidemiology of Atrial Fibrillation. Circulation. 2014;129(8):837–847. doi: 10.1161/CIRCULATIONAHA.113.005119
- Ziegler L, Hedin U, Gottsäter A. Circulating Biomarkers in Lower Extremity Artery Disease. Eur Cardiol Rev. 2022;17:e09. doi: 10.15420/ecr.2021.58
- Wu N, Xu B, Xiang Y, et al. Association of inflammatory factors with occurrence and recurrence of atrial fibrillation: A meta-analysis. Int J Cardiol. 2013;169(10):62–72. doi: 10.1016/j.ijcard.2013.08.078
- Shan J, Xie W, Betzenhauser M, et al. Calcium Leak Through Ryanodine Receptors Leads to Atrial Fibrillation in 3 Mouse Models of Catecholaminergic Polymorphic Ventricular Tachycardia. Circ Res. 2012;111(6):708–717. doi: 10.1161/CIRCRESAHA.112.273342
- Charitakis E, Tsartsalis D, Korela D, et al. Risk and protective factors for atrial fibrillation after cardiac surgery and valvular interventions: an umbrella review of meta-analyses. Open Heart. 2022;9(2):e002074. doi: 10.1136/openhrt-2022-002074
- Chung M, Martin D, Sprecher D, et al. C-Reactive Protein Elevation in Patients With Atrial Arrhythmias. Circulation. 2001;104(24):2886–2891. doi: 10.1161/hc4901.101760
- Xu Q, Bo L, Hu J, et al. High mobility group box 1 was associated with thrombosis in patients with atrial fibrillation. Medicine. 2018;97(13):e0132. doi: 10.1097/MD.0000000000010132
- Scott L, Li N, Dobrev D. Role of inflammatory signaling in atrial fibrillation. Int J Cardiol. 2019;287:195–200. doi: 10.1016/j.ijcard.2018.10.020
- Bruins P, Te V, Yazdanbakhsh A, et al. Activation of the Complement System During and After Cardiopulmonary Bypass Surgery. Circulation. 1997;96(10):3542–3548. doi: 10.1161/01.CIR.96.10.3542
- Maixet J-M, PaganelliI F, Scaglione J, Levy S. Antibodies Against Myosin in Sera of Patients with Idiopathic Paroxysmal Atrial Fibrillation. J Cardiovasc Electrophysiol. 1998;9(6):612–617. doi: 10.1111/j.1540-8167.1998.tb00942.x
- Liu T, Li G, Li L, Korantzopoulos P. Association Between C-Reactive Protein and Recurrence of Atrial Fibrillation After Successful Electrical Cardioversion. J Am Coll Cardiol. 2007;49(15):1642–1648. doi: 10.1016/j.jacc.2006.12.042
- Kutelev GG, Mirzoev NT, Ivanov VV, et al. Clinical Case of the Novel Coronavirus Infection with the Development of Cardiovascular Complications Against the Background of Comorbid Pathology. Doctor.Ru. 2022;21(6):25–28. (In Russ.). doi: 10.31550/1727-2378-2022-21-6-25-28
- Mirzoev NT, Kutelev GG, Pugachev MI, Kireeva EB. Cardiovascular complications in patients after coronavirus DISEASE-2019. Bulletin of the Russian Military Medical Academy. 2022;24(1):199–208. (In Russ.). doi: 10.17816/brmma90733
- Aulin J, Hijazi Z, Siegbahn A, et al. Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials. J Thromb Haemost. 2020;18(9):2287–2295. doi: 10.1111/jth.14947
- Roldán V, Marín F, Díaz J, et al. High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. J Thromb Haemost. 2012;10(8):1500–1507. doi: 10.1111/j.1538-7836.2012.04812.x
- Hak Ł, Myśliwska J, Wickiewicz J, et al. Interleukin-2 as a Predictor of Early Postoperative Atrial Fibrillation After Cardiopulmonary Bypass Graft (CABG). J Interferon Cytokine Res. 2009;29(6):327–332. doi: 10.1089/jir.2008.0082.2906
- Rizos I, Tsiodras S, Rigopoulos A, et al. Interleukin-2 serum levels variations in recent onset atrial fibrillation are related with cardioversion outcome. Cytokine. 2007;40(3):157–164. doi: 10.1016/j.cyto.2007.08.013
- Cabrera-Bueno F, Medina-Palomo C, Ruiz-Salas A, et al. Serum levels of interleukin-2 predict the recurrence of atrial fibrillation after pulmonary vein ablation. Cytokine. 2015;73(1):74–78. doi: 10.1016/j.cyto.2015.01.026
- Wu Z-K, Laurikka J, Vikman S, et al. High Postoperative Interleukin-8 Levels Related to Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass Surgery. World J Surg. 2008;32(12):2643–2649. doi: 10.1007/s00268-008-9758-7
- Liuba I, Ahlmroth H, Jonasson L, et al. Source of inflammatory markers in patients with atrial fibrillation. Europace. 2008;10(7): 848–853. doi: 10.1093/europace/eun111
- Choi Y-J, Choi E-K, Han K-D, et al. Increased risk of atrial fibrillation in patients with inflammatory bowel disease: A nationwide population-based study. World J Gastroenterol. 2019;25(22): 2788–2798. doi: 10.3748/wjg.v25.i22.2788
- Deng H, Xue Y-m, Zhan X-z, et al. Role of tumor necrosis factor-alpha in the pathogenesis of atrial fibrillation. Chin Med J. 2011;124(13):1976–1982.
- Nattel S. Molecular and Cellular Mechanisms of Atrial Fibrosis in Atrial Fibrillation. JACC: Clin Electrophysiol. 2017;3(5):425–435. doi: 10.1016/j.jacep.2017.03.002
- Babapoor-Farrokhran S, Gill D, Rasekhi RT. The role of long noncoding RNAs in atrial fibrillation. Heart Rhythm. 2020;17(6): 1043–1049. doi: 10.1016/j.hrthm.2020.01.015
- Rahmutula D, Zhang H, Wilson EE, Olgin JE. Absence of natriuretic peptide clearance receptor attenuates TGF-β1-induced selective atrial fibrosis and atrial fibrillation. Cardiovasc Res. 2019;115(2):357–372. doi: 10.1093/cvr/cvy224
- Doulamis IP, Samanidis G, Tzani A, et al. Proteomic profile of patients with atrial fibrillation undergoing cardiac surgery. Interact Cardiovasc Thor Surg. 2019;28(1):94–101. doi: 10.1093/icvts/ivy210
- Bouchot O, Guenancia C, Kahli A, et al. Low Circulating Levels of Growth Differentiation Factor-15 Before Coronary Artery Bypass Surgery May Predict Postoperative Atrial Fibrillation. J Cardiothorac Vasc Anesth. 2015;29(5):1131–1139. doi: 10.1053/j.jvca.2015.01.023
- Mikkelsen LF, Nordestgaard BG, Schnohr P, Ellervic C. Increased Ferritin Concentration and Risk of Atrial Fibrillation and Heart Failure in Men and Women: Three Studies of the Danish General Population Including 35799 Individuals. Clin Chem. 2019;65(1):180–188. doi: 10.1373/clinchem.2018.292763
- Amar D, Goenka A, Zhang H, et al. Leukocytosis and Increased Risk of Atrial Fibrillation After General Thoracic Surgery. Ann Thorac Surg. 2006;82(3):1057–1061. doi: 10.1016/j.athoracsur.2006.03.103
- Lamm G, Auer J, Weber T, et al. Postoperative White Blood Cell Count Predicts Atrial Fibrillation After Cardiac Surgery. J Cardiothorac Vasc Anesth. 2006;20(1):51–56. doi: 10.1053/j.jvca.2005.03.026
- Schuessler R, Ishii Y, Khagi Y, et al. The effects of inflammation on heart rate and rhythm in a canine model of cardiac surgery. Heart Rhythm. 2012;9(3):432–439. doi: 10.1016/j.hrthm.2011.09.074
- Sun Z, Zhou D, Xie X, et al. Cross-talk between macrophages and atrial myocytes in atrial fibrillation. Basic Res Cardiol. 2016;111(6):63. doi: 10.1007/s00395-016-0584-z
- Pena JM, MacFadyen J, Glynn RJ, Ridker PM. High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial. Eur Heart J. 2012;33(4): 531–537. doi: 10.1093/eurheartj/ehr460
- Maesen B, Nijs J, Maessen J, et al. Post-operative atrial fibrillation: a maze of mechanisms. Europace. 2012;14(2):159–174. doi: 10.1093/europace/eur208
- Reilly SN, Jayaram R, Nahar K, et al. Atrial Sources of Reactive Oxygen Species Vary With the Duration and Substrate of Atrial Fibrillation. Circulation. 2011;124(10):1107–1117. doi: 10.1161/CIRCULATIONAHA.111.029223
- Siu C-W, Lau C-P, Tse H-F. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol. 2003;92(11):1343–1345. doi: 10.1016/j.amjcard.2003.08.023
- Young-Xu Y, Jabbour S, Goldberg R, et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol. 2003;92(12):1379–1383. doi: 10.1016/j.amjcard.2003.08.040
- Kim YR, Nam G-B, Han S, et al. Effect of Short-Term Steroid Therapy on Early Recurrence During the Blanking Period After Catheter Ablation of Atrial Fibrillation. Circ Arrhythm Electrophysiol. 2015;8(6):1366–1372. doi: 10.1161/CIRCEP.115.002957
- Kim D-R, Won H, Uhm J-S, et al. Comparison of Two Different Doses of Single Bolus Steroid Injection to Prevent Atrial Fibrillation Recurrence after Radiofrequency Catheter Ablation. Yonsei Med J. 2015;56(2):324. doi: 10.3349/ymj.2015.56.2.324
- Ho K, Tan JA. Benefits and Risks of Corticosteroid Prophylaxis in Adult Cardiac Surgery. Circulation. 2009;119(14):1853–1866. doi: 10.1161/CIRCULATIONAHA.108.848218
- Baker WL, White CM, Kluger J, et al. Effect of perioperative corticosteroid use on the incidence of postcardiothoracic surgery atrial fibrillation and length of stay. Heart Rhythm. 2007;4(4):461–468. doi: 10.1016/j.hrthm.2006.11.026
- Koyama T, Tada H, Sekiguchi Y, et al. Prevention of Atrial Fibrillation Recurrence With Corticosteroids After Radiofrequency Catheter Ablation. J Am Coll Cardiol. 2010;56(18):1463–1472. doi: 10.1016/j.jacc.2010.04.057
- Won H, Kim J-Y, Shim J, et al. Effect of a Single Bolus Injection of Low-Dose Hydrocortisone for Prevention of Atrial Fibrillation Recurrence After Radiofrequency Catheter Ablation. Circ J. 2013;77(1):53–59. doi: 10.1253/circj.CJ-12-0728
- Iskandar S, Reddy M, Afzal MR, et al. Use of Oral Steroid and its Effects on Atrial Fibrillation Recurrence and Inflammatory Cytokines Post Ablation — The Steroid AF Study. J Atr Fibrillation. 2017;9(5):1604. doi: 10.4022/jafib.1604
- Martínez GJ, Celermajer DS, Patel S. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis. 2018;269:262–271. doi: 10.1016/j.atherosclerosis.2017.12.027
- Bouabdallaoui N, Tardif J-C, Waters DD, et al. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Eur Heart J. 2020;41(42):4092–4099. doi: 10.1093/eurheartj/ehaa659
- Hennessy T, Soh L, Bowman M, et al. The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: A pilot randomized placebo controlled trial of colchicine following acute myocardial infarction. Am Heart J. 2019;215:62–69. doi: 10.1016/j.ahj.2019.06.003
- Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119–1131. doi: 10.1056/NEJMoa1707914
- January S, Pottebaum A, Raymer D, Lavine K. Tocilizumab for Antibody-Mediated Rejection in the Setting of Cardiac Allograft Vasculopathy. J Heart Lung Transplant. 2019;38(4):S38–S39. doi: 10.1016/j.healun.2019.01.079
- Ren M, Li X, Hao L, Zhong J. Role of tumor necrosis factor alpha in the pathogenesis of atrial fibrillation: A novel potential therapeutic target? Ann Med. 2015;47(4):316–324. doi: 10.3109/07853890.2015.1042030
- Aschar-Sobbi R, Izaddoustdar F, Korogyi AS, et al. Increased atrial arrhythmia susceptibility induced by intense endurance exercise in mice requires TNFα. Nat Commun. 2015;6(1):6018. doi: 10.1038/ncomms7018
- Katoh H, Nozue T, Michishita I. Anti-inflammatory effect of factor-Xa inhibitors in Japanese patients with atrial fibrillation. Heart and Vessels. 2017;32(9):1130–1136. doi: 10.1007/s00380-017-0962-y
- Mozaffarian D, Wu JHY, de Oliveira Otto MC, et al. Fish Oil and Post-Operative Atrial Fibrillation. J Am Coll Cardiol. 2013;61(21): 2194–2196. doi: 10.1016/j.jacc.2013.02.045
- Nigam A, Talajic M, Roy D, et al. Fish Oil for the Reduction of Atrial Fibrillation Recurrence, Inflammation, and Oxidative Stress. J Am Coll Cardiol. 2014;64(14):1441–1448. doi: 10.1016/j.jacc.2014.07.956
- Gencer B, Djousse L, Al-Ramady OT, et al. Effect of Long-Term Marine ω-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. Circulation. 2021;144(25):1981–1990. doi: 10.1161/CIRCULATIONAHA.121.055654
- Jansen HJ, Mackasey M, Moghtadaei M, et al. Distinct patterns of atrial electrical and structural remodeling in angiotensin II mediated atrial fibrillation. J Mol Cell Cardiol. 2018;124:12–25. doi: 10.1016/j.yjmcc.2018.09.011
- Schneider MP, Hua TA, Böhm M, et al. Prevention of Atrial Fibrillation by Renin-Angiotensin System Inhibition. J Am Coll Cardiol. 2010;55(21):2299–2307. doi: 10.1016/j.jacc.2010.01.043
- Tang M, Chen Y, Sun F, Yan L. The Dose-Dependent Effects of Spironolactone on TGF- β1 Expression and the Vulnerability to Atrial Fibrillation in Spontaneously Hypertensive Rats. Cardiol Res Pract. 2021;2021:9924381. doi: 10.1155/2021/9924381
- Chequel M, Ollitrault P, Saloux E, et al. Preoperative Plasma Aldosterone Levels and Postoperative Atrial Fibrillation Occurrence Following Cardiac Surgery: A Review of Literature and Design of the ALDO-POAF Study (ALDOsterone for Prediction of Post-Operative Atrial Fibrillation). Curr Clin Pharmacol. 2016;11(3):150–158. doi: 10.2174/1574884711666160714162128
- Alexandre J, Ollitrault P, Fischer M-O, et al. Spironolactone and perioperative atrial fibrillation occurrence in cardiac surgery patients: Rationale and design of the ALDOCURE trial. Am Heart J. 2019;214:88–96. doi: 10.1016/j.ahj.2019.04.023